Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Care Costs | 5 | 2024 | 251 | 1.360 |
Why?
|
| Chronic Pain | 5 | 2024 | 128 | 1.330 |
Why?
|
| Depression | 8 | 2023 | 518 | 1.300 |
Why?
|
| Depressive Disorder | 7 | 2018 | 231 | 1.150 |
Why?
|
| Gastroenteritis | 2 | 2024 | 25 | 1.140 |
Why?
|
| Cost-Benefit Analysis | 10 | 2023 | 270 | 1.080 |
Why?
|
| Cost of Illness | 2 | 2024 | 100 | 1.010 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2024 | 567 | 1.000 |
Why?
|
| Adolescent | 29 | 2024 | 3798 | 0.830 |
Why?
|
| Humans | 55 | 2024 | 18430 | 0.800 |
Why?
|
| Behavior Therapy | 7 | 2023 | 155 | 0.770 |
Why?
|
| Hallucinogens | 1 | 2022 | 23 | 0.770 |
Why?
|
| Cannabis | 1 | 2022 | 78 | 0.710 |
Why?
|
| Quality of Life | 6 | 2023 | 529 | 0.700 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 249 | 0.690 |
Why?
|
| Stroke | 1 | 2022 | 311 | 0.660 |
Why?
|
| Male | 34 | 2024 | 10440 | 0.660 |
Why?
|
| Female | 39 | 2024 | 13136 | 0.650 |
Why?
|
| Anxiety Disorders | 6 | 2023 | 93 | 0.580 |
Why?
|
| Depressive Disorder, Major | 5 | 2022 | 127 | 0.570 |
Why?
|
| Child | 14 | 2024 | 2571 | 0.550 |
Why?
|
| Neoplasms | 4 | 2022 | 457 | 0.510 |
Why?
|
| Analgesics, Opioid | 4 | 2022 | 241 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 407 | 0.480 |
Why?
|
| Binge-Eating Disorder | 2 | 2010 | 13 | 0.460 |
Why?
|
| Middle Aged | 17 | 2024 | 8284 | 0.460 |
Why?
|
| Serotonin Uptake Inhibitors | 4 | 2020 | 74 | 0.450 |
Why?
|
| Electronic Health Records | 6 | 2021 | 747 | 0.400 |
Why?
|
| Adult | 18 | 2024 | 7910 | 0.400 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 444 | 0.390 |
Why?
|
| Young Adult | 11 | 2024 | 2518 | 0.370 |
Why?
|
| Acupuncture Therapy | 3 | 2017 | 36 | 0.370 |
Why?
|
| Treatment Outcome | 12 | 2022 | 1296 | 0.360 |
Why?
|
| Telemedicine | 2 | 2024 | 184 | 0.360 |
Why?
|
| Musculoskeletal Pain | 3 | 2017 | 28 | 0.360 |
Why?
|
| Aged | 9 | 2024 | 6417 | 0.330 |
Why?
|
| United States | 10 | 2024 | 4164 | 0.330 |
Why?
|
| Dental Facilities | 1 | 2009 | 2 | 0.330 |
Why?
|
| Referral and Consultation | 2 | 2017 | 180 | 0.320 |
Why?
|
| Tobacco Use Cessation | 1 | 2009 | 23 | 0.320 |
Why?
|
| Chronic Disease | 3 | 2022 | 468 | 0.320 |
Why?
|
| Health Plan Implementation | 1 | 2009 | 41 | 0.320 |
Why?
|
| Genetic Carrier Screening | 2 | 2018 | 22 | 0.310 |
Why?
|
| Combined Modality Therapy | 7 | 2014 | 150 | 0.310 |
Why?
|
| Anxiety | 4 | 2023 | 156 | 0.310 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 2 | 2022 | 14 | 0.300 |
Why?
|
| Primary Health Care | 7 | 2022 | 848 | 0.300 |
Why?
|
| Hotlines | 1 | 2007 | 16 | 0.300 |
Why?
|
| Nicotine | 1 | 2007 | 47 | 0.300 |
Why?
|
| Tobacco Use Disorder | 1 | 2007 | 49 | 0.290 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1269 | 0.290 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2020 | 39 | 0.290 |
Why?
|
| Smoking Cessation | 1 | 2007 | 199 | 0.260 |
Why?
|
| Exercise | 4 | 2021 | 495 | 0.260 |
Why?
|
| Antidepressive Agents | 3 | 2018 | 162 | 0.260 |
Why?
|
| Social Security | 1 | 2005 | 1 | 0.250 |
Why?
|
| Child, Preschool | 3 | 2024 | 1478 | 0.250 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 168 | 0.250 |
Why?
|
| Surveys and Questionnaires | 6 | 2021 | 1389 | 0.250 |
Why?
|
| Taxes | 1 | 2005 | 19 | 0.250 |
Why?
|
| Health Services Research | 3 | 2018 | 264 | 0.240 |
Why?
|
| Rural Population | 1 | 2024 | 52 | 0.240 |
Why?
|
| History, 21st Century | 1 | 2024 | 25 | 0.240 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2003 | 27 | 0.230 |
Why?
|
| Acute Disease | 1 | 2024 | 144 | 0.230 |
Why?
|
| Health Care Reform | 1 | 2003 | 33 | 0.230 |
Why?
|
| Manipulation, Chiropractic | 2 | 2015 | 22 | 0.230 |
Why?
|
| Infant | 2 | 2024 | 1245 | 0.220 |
Why?
|
| Rotavirus | 1 | 2022 | 18 | 0.210 |
Why?
|
| Rotavirus Infections | 1 | 2022 | 31 | 0.210 |
Why?
|
| Rotavirus Vaccines | 1 | 2022 | 50 | 0.210 |
Why?
|
| Medicare | 1 | 2003 | 214 | 0.210 |
Why?
|
| Cohort Studies | 4 | 2022 | 2672 | 0.210 |
Why?
|
| Vomiting | 1 | 2022 | 12 | 0.200 |
Why?
|
| Hawaii | 1 | 2022 | 45 | 0.200 |
Why?
|
| Patient Acuity | 1 | 2022 | 7 | 0.200 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2012 | 28 | 0.190 |
Why?
|
| Suicide, Attempted | 1 | 2022 | 98 | 0.190 |
Why?
|
| Pharmacy | 1 | 2021 | 12 | 0.190 |
Why?
|
| Accelerometry | 1 | 2021 | 37 | 0.190 |
Why?
|
| Cancer Survivors | 2 | 2019 | 89 | 0.190 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 129 | 0.180 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 164 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2018 | 41 | 0.170 |
Why?
|
| Survivorship | 1 | 2019 | 9 | 0.170 |
Why?
|
| Self Care | 2 | 2011 | 175 | 0.170 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2024 | 56 | 0.170 |
Why?
|
| Patient Compliance | 2 | 2019 | 318 | 0.170 |
Why?
|
| Railroads | 1 | 2019 | 5 | 0.170 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2018 | 12 | 0.160 |
Why?
|
| Neonatal Screening | 1 | 2018 | 13 | 0.160 |
Why?
|
| Environment Design | 1 | 2019 | 68 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 36 | 0.150 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 23 | 0.150 |
Why?
|
| Health Surveys | 1 | 2019 | 269 | 0.150 |
Why?
|
| Genomics | 1 | 2018 | 66 | 0.150 |
Why?
|
| Cyclohexanols | 3 | 2012 | 36 | 0.150 |
Why?
|
| Life Style | 2 | 2012 | 342 | 0.150 |
Why?
|
| Health Behavior | 3 | 2012 | 374 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2018 | 82 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 724 | 0.150 |
Why?
|
| Psychotherapy, Brief | 1 | 2017 | 20 | 0.150 |
Why?
|
| Program Evaluation | 2 | 2009 | 244 | 0.140 |
Why?
|
| Psychology, Adolescent | 1 | 2016 | 15 | 0.140 |
Why?
|
| Parents | 2 | 2020 | 309 | 0.140 |
Why?
|
| Internet | 2 | 2009 | 243 | 0.140 |
Why?
|
| Propensity Score | 1 | 2017 | 94 | 0.140 |
Why?
|
| Drug Costs | 1 | 2016 | 40 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 25 | 0.130 |
Why?
|
| Child of Impaired Parents | 1 | 2015 | 33 | 0.130 |
Why?
|
| Weight Loss | 2 | 2022 | 321 | 0.130 |
Why?
|
| Reminder Systems | 1 | 2016 | 94 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 760 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2023 | 1314 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 214 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2022 | 2550 | 0.120 |
Why?
|
| Commerce | 1 | 2014 | 49 | 0.120 |
Why?
|
| Buprenorphine | 1 | 2014 | 48 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 27 | 0.110 |
Why?
|
| Oregon | 2 | 2019 | 222 | 0.110 |
Why?
|
| Phenotype | 1 | 2013 | 148 | 0.110 |
Why?
|
| Adolescent Behavior | 2 | 2012 | 129 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2016 | 267 | 0.110 |
Why?
|
| Health Maintenance Organizations | 3 | 2015 | 479 | 0.100 |
Why?
|
| Anhedonia | 1 | 2012 | 5 | 0.100 |
Why?
|
| Counseling | 2 | 2014 | 197 | 0.100 |
Why?
|
| Bulimia | 1 | 2011 | 8 | 0.100 |
Why?
|
| Pharmacists | 2 | 2021 | 48 | 0.090 |
Why?
|
| Manuals as Topic | 1 | 2010 | 7 | 0.090 |
Why?
|
| Suicide | 1 | 2012 | 126 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 630 | 0.090 |
Why?
|
| Bone Density | 2 | 2008 | 96 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 342 | 0.090 |
Why?
|
| Overweight | 1 | 2012 | 276 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 350 | 0.080 |
Why?
|
| Self-Help Groups | 1 | 2009 | 32 | 0.080 |
Why?
|
| Diet | 2 | 2012 | 371 | 0.080 |
Why?
|
| Translational Medical Research | 1 | 2009 | 39 | 0.080 |
Why?
|
| Advertising as Topic | 1 | 2007 | 25 | 0.080 |
Why?
|
| Feeding and Eating Disorders | 1 | 2007 | 17 | 0.080 |
Why?
|
| Telephone | 1 | 2009 | 179 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2008 | 168 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 232 | 0.070 |
Why?
|
| Smoking Prevention | 1 | 2007 | 55 | 0.070 |
Why?
|
| Venlafaxine Hydrochloride | 3 | 2012 | 37 | 0.070 |
Why?
|
| Risk Factors | 2 | 2022 | 3449 | 0.070 |
Why?
|
| Health Services | 1 | 2007 | 117 | 0.070 |
Why?
|
| Northwestern United States | 2 | 2021 | 58 | 0.070 |
Why?
|
| Time Factors | 3 | 2016 | 1136 | 0.060 |
Why?
|
| Investments | 1 | 2005 | 1 | 0.060 |
Why?
|
| Health Promotion | 1 | 2007 | 294 | 0.060 |
Why?
|
| Psychometrics | 2 | 2017 | 124 | 0.060 |
Why?
|
| Pain Management | 1 | 2024 | 59 | 0.060 |
Why?
|
| Budgets | 1 | 2003 | 5 | 0.060 |
Why?
|
| Insurance Benefits | 1 | 2003 | 15 | 0.060 |
Why?
|
| Deductibles and Coinsurance | 1 | 2003 | 31 | 0.060 |
Why?
|
| Veterans | 1 | 2024 | 138 | 0.050 |
Why?
|
| Age Factors | 1 | 2005 | 965 | 0.050 |
Why?
|
| Child Health | 1 | 2023 | 34 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 157 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 105 | 0.050 |
Why?
|
| Patient Health Questionnaire | 1 | 2022 | 18 | 0.050 |
Why?
|
| Drug Resistance | 2 | 2012 | 30 | 0.050 |
Why?
|
| Vital Signs | 1 | 2021 | 14 | 0.050 |
Why?
|
| Glycated Hemoglobin A | 1 | 2022 | 233 | 0.050 |
Why?
|
| Biomarkers | 2 | 2016 | 308 | 0.050 |
Why?
|
| Sleep Hygiene | 1 | 2020 | 4 | 0.040 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 9 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 392 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 126 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2011 | 96 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 144 | 0.040 |
Why?
|
| Mentoring | 1 | 2019 | 28 | 0.040 |
Why?
|
| Communication | 1 | 2021 | 202 | 0.040 |
Why?
|
| Religion and Medicine | 1 | 2018 | 3 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 137 | 0.040 |
Why?
|
| Reproductive Health | 1 | 2018 | 12 | 0.040 |
Why?
|
| Income | 1 | 2018 | 98 | 0.040 |
Why?
|
| Preconception Care | 1 | 2018 | 48 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 402 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2018 | 327 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 847 | 0.040 |
Why?
|
| Interview, Psychological | 1 | 2016 | 19 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 256 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 15 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 10 | 0.030 |
Why?
|
| Models, Economic | 1 | 2016 | 22 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2016 | 38 | 0.030 |
Why?
|
| Health Resources | 1 | 2016 | 38 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 44 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2012 | 974 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1173 | 0.030 |
Why?
|
| Actigraphy | 1 | 2015 | 17 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 872 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 90 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 217 | 0.030 |
Why?
|
| Utilization Review | 1 | 2014 | 56 | 0.030 |
Why?
|
| Cognition | 1 | 2015 | 82 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 237 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 552 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 182 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 1143 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 1516 | 0.030 |
Why?
|
| Personality Assessment | 1 | 2012 | 15 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2012 | 10 | 0.030 |
Why?
|
| Affect | 1 | 2012 | 26 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 36 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2012 | 165 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 55 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2012 | 59 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1360 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 119 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 81 | 0.020 |
Why?
|
| California | 1 | 2017 | 2365 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 198 | 0.020 |
Why?
|
| Anorexia Nervosa | 1 | 2010 | 5 | 0.020 |
Why?
|
| Bulimia Nervosa | 1 | 2010 | 10 | 0.020 |
Why?
|
| Cost Savings | 1 | 2010 | 25 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 52 | 0.020 |
Why?
|
| Suicidal Ideation | 1 | 2011 | 100 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 2003 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2011 | 254 | 0.020 |
Why?
|
| Retention (Psychology) | 1 | 2008 | 7 | 0.020 |
Why?
|
| Calcium | 1 | 2008 | 34 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2010 | 347 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2007 | 59 | 0.020 |
Why?
|
| Office Visits | 1 | 2007 | 86 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Naltrexone | 1 | 2006 | 17 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2006 | 58 | 0.020 |
Why?
|
| Comorbidity | 1 | 2007 | 619 | 0.020 |
Why?
|
Concepts
(231)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(30)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->